Dobutamine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Dobutamine: From Cardiac Inotropic Support to Alopecia
One-Sentence Summary
Dobutamine is a short-acting intravenous β1-adrenergic agonist historically used for cardiac inotropic/hemodynamic support; this project’s structured records on its original approved indication and mechanism of action are currently gapped. The TxGNN model predicts a possible new application in Alopecia, but the supporting evidence is minimal — 0 clinical trials and only 2 tangentially related case reports, with the evidence pack itself flagging the prediction as a likely knowledge-graph artifact rather than a genuine biological signal.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not established — no Taiwan/US license on file (0 licenses). Narrative evidence in this pack describes dobutamine generically as a β1-agonist used for myocardial contractile/hemodynamic support, but a formally confirmed indication text is unavailable (data gap, see DG002). |
| Predicted New Indication | Alopecia |
| TxGNN Prediction Score | 99.85% |
| Evidence Level | L5 |
| US Market Status | Not Marketed (未上市) |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for dobutamine in this evidence pack (DG002, severity: High). Based on the information that is present — drawn from the model’s own repurposing rationale and the associated literature — dobutamine acts as a β1-adrenergic agonist that increases myocardial contractility, and it appears clinically in this pack’s supporting literature in the context of acute heart failure management and dobutamine-stress echocardiography, not dermatology.
There is no established pharmacological pathway connecting β1-adrenergic myocardial stimulation to hair follicle biology, the androgen/prostaglandin signaling implicated in alopecia, or any known hair-growth mechanism. The evidence pack’s own analysis is explicit on this point: it assesses the high TxGNN score as most likely arising from knowledge-graph node proximity — dobutamine sitting near other cardiovascular-adjacent drugs such as minoxidil (a drug with a bona fide alopecia indication) in the embedding space — rather than from any genuine shared biological mechanism. This is a textbook example of a plausible-looking but mechanistically unsupported TxGNN prediction, and it should be treated as such.
Given both the absence of a confirmed original indication in the structured record and the absence of any mechanistic rationale for the new indication, this candidate does not currently meet the bar for further pharmacological justification.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41046802 | 2025 | Case Report (Veterinary) | Journal of Veterinary Cardiology | Describes a cat with congestive heart failure where dobutamine was used for hypotension management; no hair-loss/alopecia outcome is reported — the link to alopecia is not substantive. |
| 17505274 | 2007 | Case Report | Pediatric Emergency Care | Reports acute colchicine (not dobutamine) intoxication in a child, noting hair loss during the recovery phase of colchicine poisoning; dobutamine is not the study drug and this record appears to be a mismatched/indirect literature association. |
Note: Neither publication provides direct evidence of dobutamine being used for, or effective against, alopecia. Both entries are marked “relevance: pending” in the source data and should be treated as low-quality, indirect matches rather than supportive evidence.
US Market Information
Dobutamine currently holds no market authorization on record for this jurisdiction — market status is “Not Marketed” with 0 total licenses. No product/dosage-form table is available.
Safety Considerations
Please refer to the package insert for safety information.
(Note: Key warnings, contraindications, and drug-drug interaction data are all currently gapped in this evidence pack — DG001, severity: Blocking, prevents this candidate from entering the S1 safety pre-screening stage.)
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted alopecia indication has no supporting clinical trials, only two low-relevance case reports (neither demonstrating a therapeutic effect on hair loss), and the evidence pack’s own rationale identifies the high TxGNN score as a probable knowledge-graph confounding artifact (proximity to minoxidil) rather than a real mechanistic signal. Evidence level is L5 — essentially model prediction only.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/product label warnings and contraindications to enable S1 safety pre-screening.
- Resolve DG002 (High): confirm dobutamine’s formal mechanism of action via DrugBank API to properly evaluate mechanistic plausibility.
- Establish a confirmed original/approved indication record, since none currently exists in the regulatory dataset (0 licenses, not marketed).
- If this candidate is to be pursued further despite the weak signal, independent preclinical or mechanistic evidence linking β1-adrenergic agonism to hair follicle biology would be required before any clinical hypothesis is credible.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.